Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Oct 2, 2026 - P1 | N=34 | Terminated | Sponsor: Bristol-Myers Squibb | N=105 ➔ 34 | Trial completion date: Sep 2030 ➔ Aug 2026 | Recruiting ➔ Terminated | Trial primary completion date: Feb 2027 ➔ Aug 2026; Inability to meet protocol objectives
Enrollment change • First-in-human • Monotherapy • Trial completion date • Trial primary completion date • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • CD33
|